MGH is a world leader in cancer research and education, translational medicine, and a major center for patient care. MGH has some of the world’s largest annotated tissue banks for retrospective biomarker studies as well as large and diverse patient populations for prospective studies. MGH’s Cancer Center and Department of Pathology are currently collaborating with Affymetrix to validate biomarkers of current and future clinical importance using Affymetrix’ QuantiGene ViewRNA technology platform for multiplex in situ testing of FFPE tissue biopsies, FNA cytologies, and CTC “liquid biopsies”. QuantiGene ViewRNA is an ideal platform for cancer biomarker validation and testing as RNA is a predictable, sensitive and specific alternative to antibody based IHC and ICC testing. QuantiGene ViewRNA probes for RNA assays can be developed for research applications for any expressed gene within days and can analyze non-coding RNAs believed to be important master regulators of cancer and for which antibody assays can’t be developed. To date, the research collaboration has produced several potential diagnostic/prognostic biomarker targets including new class of non-coding RNA, HSATII, and EGFR vIII.* For Research Use Only. Not for use in diagnostic procedures. About Affymetrix Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 25,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit http://www.affymetrix.com. Forward-looking statements All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2010, and other SEC reports for subsequent quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip, QuantiGene and all other trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.